Issue 141  /  July 28, 2026  /  3 min read

Wales appoints first Women's Health Minister, Delyth Jewell

Plus: A Women’s Health Summit discussed pain linked to clinical procedures, and stakeholders will draft minimum standards for service user engagement.

Wales’s first Women’s Health Minister, Delyth Jewell, committed to addressing the normalization of pain in women’s healthcare following a Women’s Health Summit on July 16, impacting patient experience and clinical practice. The summit, which included clinicians and researchers, focused on how women’s voices can shape NHS services, signaling a shift in policy and care standards. Stakeholders will now draft minimum standards for service user engagement directly impacting healthcare delivery. Five takes inside, plus a quick-hits roundup.

— The Luteal
In Today's Brief
Industry News
VIA FemTech World

“Women’s voices should be heard and pain should never be ignored,” says Wales’s first Women’s Health Minister

Wales’s first women’s health minister, Delyth Jewell, committed to addressing the normalization of pain in women’s healthcare following a Women’s Health Summit on July 16. The summit brought together clinicians and researchers to discuss pain linked to clinical procedures. Following the event, stakeholders will draft minimum standards for service user engagement.

Read the full story →
— The Luteal Editorial Team
Clinical & Research
VIA FemTech World

Only one-in-three voters say US healthcare system meeting women’s needs

Only 31% of US voters believe healthcare effectively meets women’s needs, compared to 41% for men's needs, according to a survey of 1,206 registered voters conducted by Impact Research and Echelon Insights for Center Forward between January 12-16, 2026. The survey found 92% of voters agree women have distinct health needs. This demonstrates a significant perceived care gap for women, highlighting areas of opportunity for femtech operators and investors.

Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN

Nicotinamide riboside and pterostilbene linked to reduced severity, frequency of menopause symptoms

A pilot trial observed a reduction of 50% or more in the severity and frequency of hot flashes, bloating, and poor sleep within 7 days in menopausal women. The trial attributed these improvements to nicotinamide riboside and pterostilbene. This research presents a potential non-hormonal treatment avenue for menopausal symptom management.

Read the full story →
— The Luteal Editorial Team
More